Loss-of-function mechanisms in Huntington's Disease
Loss-of-function mechanisms in Huntington's Disease
批准号:
8015208
负责人:
Scott Zeitlin
金额:
$32.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-03-01 至 2014-01-31
关键词:
20qAffectAllelesAutophagocytosisAutophagosomeBehavioralBindingBinding ProteinsBiochemicalBrainCell Culture TechniquesCellsCessation of lifeComplexCorpus striatum structureDataDiseaseDominant-Negative MutationDynein ATPaseEpitopesExhibitsGenesGeneticGoalsHumanHuntington DiseaseIn VitroKnock-outKnockout MiceLengthLongevityLysosomesMeasuresMediatingMinus End of the MicrotubuleMovementMusMutant Strains MiceMutationNervous System Heredodegenerative DisordersNeurodegenerative DisordersNeuronsOrganellesPathogenesisPathway interactionsPhenotypePlayPolyubiquitinProcessProteinsResearchResistanceRoleStretchingSymptomsTRAF6 geneTestingTherapeuticTissuesTrinucleotide RepeatsWorkbasedesigndisease phenotypegain of functiongain of function mutationhuman Huntingtin proteinloss of functionmouse modelmutantnestin proteinnovelnovel therapeuticspolyglutamineprotein aggregatepublic health relevanceresearch studyretrograde transporttreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Huntington's disease (HD) is a dominant neurodegenerative disease that is caused by the expansion of a stretch of CAG triplet repeats encoding polyglutamine (polyQ) within huntingtin (htt), the protein product of the HD gene. HD is considered to be the consequence of a deleterious gain-of-function caused by the expanded polyQ stretch that is unrelated to htt's normal function. Recent work suggests that although gain-of-function may play an important role in HD pathogenesis, a corresponding loss of normal htt function also contributes to the disease process. Our long-term objective is to use genetic and biochemical approaches to understand the role of htt's normal function in HD pathogenesis, and to discover new potential therapeutic strategies for the treatment of HD based on restoring normal htt function in HD. To accomplish this objective, we propose three specific aims that are designed to help us understand how the expanded polyQ stretch can affect normal htt function, and how a version of htt that lacks its normal short stretch of polyQ (?Q-htt) is able to rescue HD phenotypes in a mouse model for HD. In Aim 1, we will test the hypothesis that ?Q-htt is able to rescue HD mouse model phenotypes by enhancing autophagic clearance of mutant htt. We will use both cell culture and mouse models to focus on two potential mechanisms that may be responsible for ?Q-htt's effects. First, ?Q-htt may mediate the enhanced recognition of mutant htt aggregates by p62/SQSTM1, a polyubiquitin binding protein that can target such aggregates for autophagic degradation. Second, ?Q-htt may affect autophagic degradation of mutant htt aggregates indirectly by enhancing retrograde transport of autophagosomes to lysosomes. To test these mechanisms, we will characterize brains and primary neurons derived from mice expressing ?Q-htt with or without 140Q-htt expression, and conditional knockout mice lacking neuronal htt expression, for p62/SQSTM1 function. In addition, the efficiency of retrograde transport will be characterized in primary neuronal cultures by measuring organelle and dynein complex movement. Recently, we have also observed that increasing the length of the mouse htt polyQ stretch from 7Q to the normal human average length of 20Q can accelerate interactions of normal and mutant htt. To test the hypothesis that an interaction between normal and mutant htt can affect HD pathogenesis, we will compare in Aim 2, behavioral and neuropathological phenotypes in mice expressing 7Q/140Q htt, and in mice expressing 20Q/140Q htt. Finally, in Aim 3, we will test the hypothesis that ?Q-htt may interact with a novel set of binding partners and/or is resistant to 140Q-htt's potential to influence the interaction of htt with its binding partners, by using mice expressing epitope-tagged htt alleles to detect differences in the repertoire of normal and ?Q-htt interacting proteins in the presence and absence of mutant htt expression.
PUBLIC HEALTH RELEVANCE: Huntington's disease (HD) is a hereditary neurodegenerative disease affecting ~1 in 10,000 people that is caused by a mutation in the protein huntingtin (htt). There is currently no cure for this disorder, and once symptoms are detected, the disease progresses over 10-20 years and ends inevitably in death. We propose experiments that will help us to understand how the mutation affects htt normal function so that we can discover new therapeutic strategies based on restoring htt function in people affected with HD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice
-
批准号:10556339
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2022
-
负责人:Scott Zeitlin
-
依托单位:
Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice
-
批准号:10340336
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2022
-
负责人:Scott Zeitlin
-
依托单位:
Modeling the effects of reducing huntingtin and Hdh alternative splicing in mice
-
批准号:8911911
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2015
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:8838533
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:9313949
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:9109070
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:8932828
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Reversible conditional models for Huntington's disease
-
批准号:8223374
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2011
-
负责人:Scott Zeitlin
-
依托单位:
Reversible conditional models for Huntington's disease
-
批准号:8323915
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2011
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6862649
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7194241
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6617512
-
项目类别:
-
资助金额:$31.04万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8416970
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:7781699
-
项目类别:
-
资助金额:$33.49万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7027007
-
项目类别:
-
资助金额:$30.89万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6701761
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8220937
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7687132
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2002
-
负责人:Scott Zeitlin
-
依托单位:
海外基金